The FDA has approved a new pre-filled syringe administration route for efgartigimod (Vyvgart; Argenx), a marketed medication for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The decision offers patients greater convenience and flexibility, allowing in-home administration and reducing the number of time-consuming trips that typically come with intravenous infusions.
